Conatus Pharmaceuticals Inc (CNAT) Given Average Recommendation of “Buy” by Brokerages

Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have earned an average recommendation of “Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $11.00.

CNAT has been the subject of several analyst reports. Oppenheimer set a $14.00 price objective on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 1st. ValuEngine lowered shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Monday, November 5th.

Shares of NASDAQ:CNAT traded down $0.39 during trading on Monday, reaching $5.34. 621,677 shares of the company traded hands, compared to its average volume of 641,022. The firm has a market capitalization of $159.48 million, a P/E ratio of -8.75 and a beta of 1.84. Conatus Pharmaceuticals has a 1-year low of $3.22 and a 1-year high of $7.95. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 0.83.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%. The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $9.70 million. Equities research analysts expect that Conatus Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Artal Group S.A. acquired a new stake in shares of Conatus Pharmaceuticals in the 3rd quarter valued at $2,900,000. BlackRock Inc. lifted its position in Conatus Pharmaceuticals by 13.4% during the 3rd quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock worth $9,419,000 after acquiring an additional 191,287 shares during the last quarter. Jane Street Group LLC acquired a new position in Conatus Pharmaceuticals during the 2nd quarter worth $142,000. Paloma Partners Management Co acquired a new position in Conatus Pharmaceuticals during the 2nd quarter worth $547,000. Finally, Bank of America Corp DE lifted its position in Conatus Pharmaceuticals by 75.7% during the 2nd quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock worth $602,000 after acquiring an additional 60,604 shares during the last quarter. 33.47% of the stock is owned by institutional investors and hedge funds.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Recommended Story: Rule of 72

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply